These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21736693)

  • 21. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
    Siddiqui SA; Inman BA; Sengupta S; Slezak JM; Bergstralh EJ; Leibovich BC; Zincke H; Blute ML
    Cancer; 2006 Aug; 107(3):521-9. PubMed ID: 16773619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D; Pickles T; Tyldesley S;
    BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database.
    Fitzsimons NJ; Sun LL; Dahm P; Moul JW; Madden J; Gan TJ; Freedland SJ
    Urology; 2007 Dec; 70(6):1146-51. PubMed ID: 18158036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laparoscopic radical prostatectomy and body mass index: an assessment of 151 sequential cases.
    Brown JA; Rodin DM; Lee B; Dahl DM
    J Urol; 2005 Feb; 173(2):442-5. PubMed ID: 15643198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
    Pfitzenmaier J; Pritsch M; Haferkamp A; Jakobi H; Fritsch F; Gilfrich C; Djakovic N; Buse S; Pahernik S; Hohenfellner M
    BJU Int; 2009 Apr; 103(7):877-82. PubMed ID: 19007372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
    Freedland SJ; Isaacs WB; Mangold LA; Yiu SK; Grubb KA; Partin AW; Epstein JI; Walsh PC; Platz EA
    Clin Cancer Res; 2005 Apr; 11(8):2883-8. PubMed ID: 15837737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Grubb RL; Black A; Izmirlian G; Hickey TP; Pinsky PF; Mabie JE; Riley TL; Ragard LR; Prorok PC; Berg CD; Crawford ED; Church TR; Andriole GL;
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):748-51. PubMed ID: 19258472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
    van Roermund JG; Kok DE; Wildhagen MF; Kiemeney LA; Struik F; Sloot S; van Oort IM; Hulsbergen-van de Kaa CA; van Leenders GJ; Bangma CH; Witjes JA
    BJU Int; 2009 Aug; 104(3):321-5. PubMed ID: 19220264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.